-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

654A.O1.6 654. Multiple Myeloma: Pharmacologic Therapies: Refining the Evidence: Randomized Trials in Multiple Myeloma

Symposia: Multiple Myeloma: Pharmacologic Therapies Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Clinical trials, Combination therapy, Adult, Drug development, Elderly, Clinical Practice (Health Services and Quality), Clinical Research, Plasma Cell Disorders, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies, Adverse Events, Monoclonal Antibody Therapy, Study Population, Human, Measurable Residual Disease
Monday, December 9, 2024: 10:30 AM-12:00 PM
Pacific Ballroom Salons 21-22 (Marriott Marquis San Diego Marina)
Moderators:
Shohei Mizuno, MD, PhD, Aichi Medical University and Nisha S. Joseph, MD, Winship Cancer Institute of Emory University
Disclosures:
Mizuno: Hayashikane Sangyo: Research Funding; Janssen pharmaceutical: Honoraria.
This Session Brings Initial Disclosure of Randomized Trials in Multiple Myeloma and Important Secondary Analysis and Long Term Follow-up of Previously Reported Trials. The Abstracts Presented Will Inform New Evidence for Treatment of Smoldering Multiple Myeloma, New Combinations in the Management of Newly Diagnosed Multiple Myeloma and the Role of Drugs with New Mechanism of Action in the Treatment of Relapsed Multiple Myeloma
10:30 AM

Hartmut Goldschmidt, MD1,2, Uta Bertsch, MD3,4*, Ema Pozek5*, Axel Benner6*, Roland Fenk, MD, PhD7*, Britta Besemer, MD8*, Christine Hanoun9*, Roland Schroers, MD10*, Ivana von Metzler, MD11*, Mathias Hänel, MD12, Christoph Mann, MD13*, Lisa Leypoldt, MD14*, Bernhard Heilmeier15*, Stefanie Huhn, PhD16*, Sabine Vogel, PhD17*, Michael Hundemer, MD18*, Christof Scheid, MD19, Igor Wolfgang Blau, MD, PhD20*, Steffen Luntz, MD21*, Tobias A.W. Holderried, MD22*, Karolin Trautmann-Grill23*, Deniz Gezer, MD24*, Maika Klaiber-Hakimi25*, Martin Mueller, MD26*, Evgenii Shumilov27*, Wolfgang Knauf, MD28*, Christian Sebastian Michel, MD29*, Thomas Geer, MD30, Hendrik Riesenberg31*, Christoph Lutz32*, Marc-Steffen Raab33*, Martin Hoffmann34*, Katja C. Weisel, MD35, Hans Salwender, MD36* and Elias K. Mai, MD37*

1Internal Medicine V, GMMG - Study Group at University Hospital Heidelberg, Heidelberg, Germany
2National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany
3National Center for Tumor Diseases Heidelberg, Heidelberg, Germany
4Internal Medicine V, Hematology, Oncology and Rheumatology, GMMG Studygroup, Heidelberg University Hospital, Heidelberg, Germany
5German Cancer Research Center, Heidelberg, DEU
6Division of Biostatistics, German Cancer Research Center (DKFZ), Heidelberg, Germany
7Department of Haematology, Oncology, and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany
8Department of Internal Medicine II, University Hospital Tübingen, Tübingen, Germany
9Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer consortium (DKTK partner site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, Germany
10Knappschaftskrankenhaus Bochum, University Hospital Bochum, Bochum, Germany
11Department of Medicine II – Hematology and Oncology, Goethe-University Frankfurt, University Hospital, Frankfurt am Main, Germany
12Department of Internal Medicine III, Klinikum Chemnitz, Chemnitz, Germany
13Department of Haematology, Oncology and Immunology, Philipps-University Marburg, Marburg, Germany
14University Medical Center Hamburg Eppendorf, Hamburg, Germany
15Clinic for Oncology and Hematology, Hospital Barmherzige Brueder Regensburg, Regensburg, Germany, Regensburg, DEU
16Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany
17Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany, Heidelberg, Germany
18Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
19Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany
20Medical Clinic, Charité University Medicine Berlin, Berlin, Germany
21Coordination Centre for Clinical Trials (KKS), Heidelberg, Germany
22Department of Hematology, Oncology, Stem Cell Transplantation, Immune and Cell Therapy, Clinical Immunology and Rheumatology, University Hospital Bonn, Bonn, Germany
23University Hospital Carl Gustav Carus, Dresden, Germany
24Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, DEU
25Clinic for Hematology, Oncology and Palliative Care, Marien Hospital Düsseldorf, Düsseldorf, Germany, Duesseldorf, DEU
26Klinikum Siloah Hannover, Hannover, Germany, Hannover, AL, DEU
27Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany
28Center for Hematology and Oncology, Bethanien, Frankfurt a.M., Germany, Frankfurt a.M., Germany
29Department of Internal Medicine III, University Hospital Mainz, Mainz, Germany
30Medizinische Klinik Schwäbisch-Hall, Schwabisch Hall, DEU
31Hematology / Oncology Center, Bielefeld, Germany, Bielefeld, Germany
32Hematology / Oncology Center, Koblenz, Germany, Koblenz, Germany
33Department of Medicine V, Heidelberg Myeloma Center, University Hospital Heidelberg, Heidelberg, Germany
34Medical Clinic A, Clinic Ludwigshafen, Ludwigshafen, Germany, Ludwigshafen, Germany
35Department of Oncology, Hematology and BMT, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany
36Asklepios Tumorzentrum Hamburg, Asklepios Hospital Hamburg Altona and St. Georg, Hamburg, Germany
37Heidelberg Myeloma Center, Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany

10:45 AM

Robert Z. Orlowski, MD, PhD1, Meletios-Athanasios Dimopoulos2, Xavier Leleu3, Zhuogang Liu4*, Tadao Ishida5, Roman Hajek, MD, PhD6, Ivan Špička7*, Joanna Romejko-Jarosinska, MD, PhD8*, Vladimir I. Vorobyev, PhD9*, Britta Besemer, MD10*, Sevgi Beşışık, MD11*, Pawel Robak12*, Hartmut Goldschmidt, MD13, Thomas Martin, MD14, Mohamad Mohty, MD, PhD15, Sandrine Macé, PhD16*, Ercem Kodas, PhD16*, Christina Tekle17*, Andrea Shafer17* and Philippe Moreau, MD, PhD18*

1Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Clinical Therapeutics, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
3Service d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402, Poitiers, France
4Shengjing Hospital of China Medical University, Shenyang, China
5Japanese Red Cross Medical Center, Tokyo, Japan
6Department of Hemato-Oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
7Charles University and General Hospital in Prague, Prague, Czech Republic
8Department of Lymphoid Malignancies, Marie Sklowdoska-Curie National Research Institute of Oncology, Warszawa, Poland
9S.P. Botkin Moscow City Clinical Hospital, Moscow, Russian Federation
10Department of Hematology, Oncology, Immunology and Rheumatology, University Hospital of Tuebingen, Tuebingen, Germany
11Department of Internal Medicine, Istanbul Medical Faculty, Istanbul, Turkey
12Department of General Hematology, Copernicus Memorial Hospital, Comprehensive Cancer Center and Traumatology, Łódź, Poland
13Internal Medicine V, Hematology, Oncology and Rheumatology, GMMG Studygroup, Heidelberg University Hospital, Heidelberg, Germany
14Department of Hematology, University of California at San Francisco, San Francisco, CA
15Department of Hematology, Hôpital Saint-Antoine, Sorbonne University and INSERM, Paris, France
16Sanofi, R&D, Vitry-sur-Seine, France
17Sanofi, Cambridge, MA
18University Hospital Hôtel-Dieu, Nantes, France

11:00 AM

Charlotte Pawlyn, PhD1,2, Faith E Davies, MD3, Martin F Kaiser, MD1,2, Ruth M de Tute, MSc, PhD, FRCPath4*, Heather McIntyre5*, Jeanine Richards5*, Sharon Jackson5*, Elizabeth Hodson5*, Anna Hockaday5*, Catherine Olivier5*, John R Jones6,7,8*, Matthew W. Jenner9*, Gordon Cook, PhD, DSc10*, Walter Martin Gregory, PhD5*, Mark Drayson11*, Roger G Owen, MD, MRCP, FRCPath4*, Gareth Morgan, M.D., Ph.D.3*, David A. Cairns, PhD10* and Graham Jackson, MD12*

1The Institute of Cancer Research, London, United Kingdom
2The Royal Marsden NHS Foundation Trust, London, United Kingdom
3Perlmutter Cancer Center, Multiple Myeloma Research Program, NYU Langone Health, New York, NY
4HMDS, Leeds Cancer Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
5Leeds Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
6Kings College Hospital, London, United Kingdom
7Brighton and Sussex Medical School, Brighton, United Kingdom
8East Sussex NHS Trust, Eastbourne, United Kingdom
9University Hospital Southampton, Southampton, United Kingdom
10Cancer Research UK Clinical Trials Unit, Leeds Institute of Clinical Trials Research, University of Leeds, Leeds, United Kingdom
11University of Birmingham, Institute of Immunology and Immunotherapy, Birmingham, United Kingdom
12University of Newcastle, Department of Haematology, Newcastle, United Kingdom

11:15 AM

Vania Hungria, MD, PhD1, Pawel Robak, MD, PhD2*, Marek Hus, MD, PhD3*, Vera Zherebtsova, MD4*, Christopher Ward, MD, PhD5*, Phoebe Joy Ho, MBBS6, Roman Hajek, MD, PhD7, Kihyun Kim, MD8*, Sebastian Grosicki, MD, PhD9*, Hanlon Sia, MBBS FRACP FRCPA10*, Adam Bryant, MBBS(Hon), PhD, FRACP, FRCPA11*, Marcelo Pitombeira de Lacerda, MD, PhD12*, Gracia Aparecida Martinez, MD, PhD13*, Anna Maria Sureda Balarí, MD, PhD14, Irwindeep Sandhu, MD15, Claudio Cerchione, MD16, Peter Ganly, BMBCh, PhD17, Meletios Dimopoulos, MD18, Chengcheng Fu19*, Mamta Garg, MD20*, Al-Ola Abdallah, MD21, Moshe E Gatt, MD22, Albert Oriol, MD23*, Michele Cavo, MD24*, Robert Rifkin, MD, FACP25, Tomoaki Fujisaki, MD, PhD26*, Michał Mielnik, MD3*, Nick Pirooz, MHA27*, Joe Lee, PhD28*, Astrid McKeown, PhD29*, Rachel Rogers, MS27*, Hena Baig, BS30*, Lydia Eccersley, MBBS, MRCP, FRCPath, PhD28*, Sumita Roy-Ghanta, MD27* and Maria Victoria Mateos, MD, PhD31

1Clinica São Germano, São Paulo, Brazil
2Medical University of Lodz, Lodz, Poland
3Medical University of Lublin, Lublin, Poland
4Gorodskaya Klinicheskaya Bol’nitsa Im. S.p. Botkina, Moscow, Russian Federation
5Royal North Shore Hospital, Sydney, NSW, Australia
6Royal Prince Alfred Hospital, Camperdown, NSW, Australia
7University Hospital Ostrava and University of Ostrava, Ostrava, Czech Republic
8Sungkyunkwan University, Samsung Medical Center, Seoul, Korea, Republic of (South)
9Medical University of Silesia, Katowice, Poland
10Pindara Private Hospital, Gold Coast, Australia
11Liverpool Hospital, Sydney, Australia
12Universidade da Região de Joinville (Univille), Joinville, Santa Catarina, Brazil
13Hospital das Clínicas and Instituto do Câncer do Estado de São Paulo, Universidade de São Paulo, São Paulo, Brazil
14Institut Català d'Oncologia-L'Hospitalet L.-Barcelona, Barcelona, Spain
15Cross Cancer Institute, Edmonton, AB, Canada
16Hematology Unit, Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST IRCCS, Meldola (FC), Italy
17Christchurch Hospital, Christchurch, New Zealand
18National and Kapodistrian University of Athens, Athens, Greece
19The First Affiliated Hospital of Soochow University, Suzhou, China
20University Hospitals of Leicester NHS Trust, Leicester, United Kingdom
21University of Kansas Cancer Center, Fairway, KS
22Department of Haematology, Hadassah Medical Center, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
23Institut Català d’Oncologia and Josep Carreras Research Institute, Hospital Germans Trias i Pujol, Badalona, Spain
24Istituto di Ematologia "Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
25Rocky Mountain Cancer Centers - Denver – Midtown, Denver, CO
26Matsuyama Red Cross Hospital, Matsuyama, Japan
27GSK, Upper Providence, PA
28GSK, London, United Kingdom
29GSK, Stevenage, United Kingdom
30GSK, Mississauga, Ontario, CAN
31Hospital Universitario de Salamanca/IBSAL/CIC/Ciberonc, Salamanca, Spain

11:30 AM

Meletios-Athanasios Dimopoulos1, Peter M. Voorhees, MD2, Fredrik Schjesvold, MD, PhD3, Yael C. Cohen4, Vania Hungria, MD, PhD5, Irwindeep Sandhu, MD6*, Jindriska Lindsay, FRCP FRCPath7*, Ross Ian Baker, MBBS, BSc, FRACP, FRCPA8, Kenshi Suzuki, MD, PhD9, Hiroshi Kosugi, MD10*, Mark-David Levin11, Meral Beksac12*, Keith Stockerl-Goldstein13*, Albert Oriol14*, Gabor Mikala15*, Gonzalo Martin Garate, MD16*, Koen Theunissen17*, Ivan Spicka, CSc18*, Anne K. Mylin19*, Sara Bringhen, MD, PhD20, Katarina Uttervall21*, Bartosz Michal Pula, MD, PhD22*, Eva Medvedova, MD23*, Andrew J. Cowan, MD24*, Philippe Moreau, MD, PhD25*, Maria-Victoria Mateos, MD, PhD26, Hartmut Goldschmidt, MD27, Tahamtan Ahmadi, MD, PhD28*, Linlin Sha, PhD29*, Els Rousseau30*, Liang Li29*, Robyn M. Dennis31*, Robin Carson, MD32 and Vincent Rajkumar, MD33*

1National and Kapodistrian University of Athens, Alexandra General Hospital, Athens, Greece
2Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC
3Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway
4Tel-Aviv Sourasky (Ichilov) Medical Center, and Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
5Clinica São Germano, São Paulo, Brazil
6University of Alberta, Cross Cancer Institute, Edmonton, AB, Canada
7Kent and Canterbury Hospital, Kent, United Kingdom
8Perth Blood Institute, Murdoch University, Perth, Australia
9Japanese Red Cross Medical Center, Tokyo, Japan
10Ogaki Municipal Hospital, Ogaki City, Japan
11Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, Netherlands
12Ankara Liv Hospital, Istinye University, Ankara, Turkey
13Washington University School of Medicine, St. Louis, MO
14Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain
15South Pest Central Hospital, National Institute for Hematology and Infectious Diseases, Budapest, Hungary
16Department of Hematology, Hospital Alemán, Buenos Aires, Argentina
17Jessa Hospital, Hasselt, Belgium
18Charles University and General Hospital, Prague, Czech Republic
19Department of Hematology, Rigshospitalet, Copenhagen, Denmark
20SSD Clinical Trials in Oncol-ematologia e Mieloma Multiplo, AOU Città della Salute e della Scienza di Torino, Torino, Italy
21Hematology Medical Unit, Karolinska University Hospital, Stockholm, Sweden
22Institute of Hematology and Transfusion Medicine, Warszawa, Poland
23Knight Cancer Institute, Oregon Health & Science University, Portland, OR
24University of Washington and Fred Hutchinson Cancer Center, Seattle, WA
25University Hospital Hôtel-Dieu, Nantes, France
26University Hospital of Salamanca/IBSAL/Cancer Research Center-IBMCC (USAL-CSIC), Salamanca, Spain
27GMMG-Study Group at University Hospital Heidelberg, Internal Medicine V, Heidelberg, Germany
28Genmab, Plainsboro, NJ
29Janssen Research & Development, LLC, Shanghai, China
30Janssen Research & Development, Beerse, Belgium
31Janssen Research & Development, LLC, Raritan, NJ
32Janssen Research & Development, LLC, Spring House, PA
33Division of Hematology, Mayo Clinic, Rochester, MN

11:45 AM

Salomon Manier, MD, PhD1, Jérome Lambert, MD, PhD2*, Cyrille Hulin, MD3*, Kamel Laribi, MD4*, Carla Araujo5*, Gian Matteo Pica, MD6*, Cyrille Touzeau, MD, PhD7*, Pascal Godmer8*, Bohrane Slama9*, Lionel Karlin10*, Frederique Orsini Piocelle, MD11*, Mamoun Dib12*, Magaret Macro, MD13*, Laurence Sanhes, MD14*, Lydia Montes, MD15*, Abderrazak El Yamani, MD16*, Mourad Tiab, MD17*, Reza Tabrizi18*, Laurent Garderet, MD, PhD19*, Bruno Royer, MD20*, Benoit Bareau21*, Aurore Perrot, MD, PhD22, Jean Yves Mary23*, Jill Corre, PharmD, PhD24*, Herve Avet Loiseau, MD, PhD25, Philippe Moreau, MD, PhD26*, Xavier Leleu27 and Thierry Facon, MD28

1Lille University Hospital, Lille, France
2Biostatistics and Medical Information Department, Saint Louis University Hospital, AP-HP, Université Paris Cité, Paris, FRA
3Hôpital Haut Lévêque, University Hospital, Pessac, France
4Hematology Department, Le Mans Hospital, Le Mans, France
5CH Bayonne, Bayonne, FRA
6Département d'Hématologie, CH Chambery, Chambéry, France
7Centre Hospitalier Universitaire de Nantes, Nantes, France
8CH Vannes, Vannes, FRA
9Service d'onco-hématologie, Centre Hospitalier Général d'Avignon, Avignon, FRA
10Department of Hematology, Lyon Sud Hospital, Pierre Benite, France
11hematology, ANNECY Hospital, annecy, France
12Chu Angers, Angers, FRA
13CHU de Caen, Caen, France
14Centre Hospitalier Perpignan, Perpignan, France
15CHU Amiens-Picardie, Amiens, France
16Centre Hospitalier de Blois, Blois, FRA
17Centre Hospitalier Departemental, La Roche Sur Yon Cedex 9, FRA
18CH Mont de Marsan, Mont De Marsan, FRA
19Hôpital la pitié salpetriere, Paris, FRA
20Department of Immuno-hematology, Hôpital Saint Louis, APHP, Paris, France
21Cabinet Medicale, Rennes, FRA
22Hématologie, Institut Universitaire du Cancer de Toulouse (IUCT) Oncopole, Toulouse, France
23INSERM, Paris, FRA
24Institut Universitaire du Cancer de Toulouse Oncopole, Toulouse, France
25Unité Génomique du Myélome, University Hospital Toulouse, IUCT Oncopole, Toulouse, France
26Hematology, University Hospital of Nantes, Nantes, France
27Poitiers University Hospital, Poitiers, France
28University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France

*signifies non-member of ASH